Effects of selective imidazolin-1 receptor agonists’ vs Dihydropyridine calcium channel blockers on insulin resistance in patients of hypertension with metabolic syndrome: a meta-analysis of randomized controlled trials
Keywords:I1 receptor agonists, Dihydropyridines, Insulin resistance, Hypertension
Background: Co-existence of insulin resistance in pre-diabetic hypertensive patients is associated with the higher risk for onset of diabetes and higher incidences of cardiovascular events in existing diabetics. Hence there is a need for selecting an anti-hypertensive drug with favourable metabolic effects. Present study aims at comparing the metabolic and hemodynamic effects of selective imidazolin-1 (I1) receptor agonists vs dihydropyridines (DHPs).
Methods: After electronic data base search in PUBMED, Cochrane library and EMBASE, total four RCTs were found eligible and included in analysis. Two studies used moxonidine (0.2-0.4mg), other two used rilmenidine (1-2mg) as selective I1-agonists and among DHPs, amlodipine (5-10mg) was used in three studies and isradipine (5-10mg) in one.
Results: Use of DHPs was associated with significant decrease in DBP (MD = -2.37mm Hg; 95% CI:-1.39, -3.36) both at the end of short-term (3 months) and long-term (6 months) treatment. Significant decrease in fasting serum insulin level (MD = -2.63mU/L; 95% CI:-4.66, -0.60) and HOMA index for insulin resistance (MD = -1.14, 95% CI:-1.48, -0.80) observed in patients treated with I1-agonists at three months were not persistent at the end of six months. Effects of both groups of drugs on plasma lipids concentration were inconclusive.
Conclusions: In addition to the concern over safety of I-1 agonists in heart failure patients, there is a lack of data on therapeutic benefits of I1-agonists on cardiovascular related events in hypertension. Hence for time being and with available evidences, DHPs seem to be better choice than I1-agonists in hypertensive patients with metabolic syndrome.
Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetology & Metabolic Syndrome. 2014;6(12):1-8.
Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol. 2014;6(7):517-30.
Abel ED, O’shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32:2068-76.
Jia G, Aroor AR, Demarco VG, Martinez-Lemus LA, Meininger GA, Sowers JR. Vascular stiffness in insulin resistance and obesity. Front. Physiol. 2015;6:(231):1-8.
Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. Circulation. 2003;107:1448-53.
Furberg CD, Wright JT, Davis BR, Cuttler JA, Alderman M, Black H. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981-97.
González-juanatey JR. After the ALLHAT trial, what do we know about treatment for hypertension that we did not know before?. Rev Esp Cardiol. 2003;56(7):642-8.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-92.
Cooper-dehoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF. INVEST revisited: A review of findings from the international verapamil SR-trandolapril study (INVEST). Expert Rev Cardiovasc Ther. 2009;7(11):1329-40.
Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047-56.
Agodoa L, Baigent C, Black H, Boissel JP, Brenner B. Effects of different blood pressure–lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med. 2005;165:1410-9.
Schachter M. Metabolic effects of moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab. 1999;1(6):317-22.
Torres YC, Katholi RE. Novel treatment approaches in hypertensive type 2 diabetic Patients. World J Diabetes. 2014;5(4):536-45.
Hansson L. Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Blood Press suppl. 1998;3:20-2.
Nancy GB, Robert AP. Meta-analysis: neither quick nor easy. BMC medical research methodology. 2002;2:10.
Masajtis ZA, Majer J, Nowicki M. Effect of moxonidine and amlodipine on serum Ykl-40, plasma lipids and insulin sensitivity in Insulin-resistant hypertensive patients - A randomized, crossover trial. Hypertension research. 2010;33:348-53.
Sanjuliani AF, De Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive Patients. Int J Clin Pract. 2006;60(5):621-29.
De lucaa N, Iizzoa R, Fontanaa D, Iovinoa G, Argenzianoa L, Vecchioneb C. Haemodynamic and metabolic effects of rilmenidine in Hypertensive patients with metabolic syndrome X. A Double-blind parallel study versus amlodipine. Journal of hypertension. 2000;18:1515-22.
Widimský JA, Sirotiaková J. Efficacy and tolerability of rilmenidine compared with is radipine in hypertensive patients with features of metabolic syndrome. Current Medical Research and Opinion. 2006;22:1287-94.
Regunathan S, Reis DJ. Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. Hypertension. 1997;30:295-300.
Regunathan S, Youngson C, Raasch W, Wang H, Reis DJ. Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. J Pharmacol Exp Ther. 1996;276(3):1272-82.
Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the n(g)-nitro-l-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res. 2005;28(8):689-700.
Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010;32(2):121-8.
Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'connor C. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy. JCHF. 2013;1(4):308-14.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659-67.
Shannon HE, Lutz EA. Effects of the I (1) imidazoline/alpha (2)-adrenergic receptor agonist moxonidine in comparison with clonidine in the formalin test in rats. Pain. 2000;85(1-2):161-7.
Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists their pharmacology and therapeutic role. Anaesthesia. 1999;54:146-65.
Bhattacharya S, Dey D, Sankar SR. J. Molecular mechanism of insulin resistance. Biosci. 2007;32(2):405-13.
Boden G. Role of fatty acids in the pathogenesis of insulin Resistance and NIDDM. Diabetes. 1996;45:3-10.